Codex

The People

Governance looks like a B-: Cigna has real capital discipline and a strong outside board bench, but regulatory baggage and a CEO-to-Executive-Chair handoff keep trust below the top tier.

The People Running This Company

Cordani deserves credit for the Express Scripts integration, the Evernorth build-out, and the willingness to exit Medicare Advantage rather than defend a weaker position. That said, the March 3, 2026 succession plan is governance-messy: Brian Evanko gets the CEO job, but Cordani stays in the chair as Executive Chair, which preserves continuity while weakening the board’s ability to show a clean oversight reset.

Evanko is the key operating figure to watch because he brings insurance, finance, and enterprise execution experience in one person. Dennison is the wild card: an external CFO can improve challenge culture, but the source pack is still too early to say whether she materially changes capital discipline or disclosure quality.

What They Get Paid

The absolute dollars are high, but the structure is not obviously abusive: Cordani’s package is overwhelmingly performance-linked equity rather than cash salary, and Evanko and Palmer sit near the $10 million mark rather than anywhere close to Cordani’s level. More encouragingly, Cigna said in 2025 that more leadership compensation now incorporates customer-experience measures such as NPS, which is at least moving incentive design toward service quality rather than pure financial engineering.

The real reservation is not that pay is egregious on its face. It is that the source pack does not include the primary proxy tables, so the best local evidence is still one step removed from the filing. In a company with active regulatory scrutiny, compensation needs to be easy to verify, not merely easy to summarize.

Are They Aligned?

This is the best part of the governance case. Aggregate insider ownership is only about 1.4%, but in dollar terms it is still roughly $1.1 billion, and the board has paired that with aggressive shareholder returns: about $7.0 billion of buybacks in 2024 and $3.6 billion in 2025, plus a steady dividend. That is not the behavior of a management team that treats the equity as incidental.

Still, alignment is not clean enough for a higher score. Open-market insider activity has skewed negative in 2024 and 2025, and a lot of the ownership story depends on grants and option events rather than repeated cash buying. I also did not find concrete self-dealing in the local pack, but the missing primary proxy related-party table means I cannot fully clear that box. The governance guidelines are strong on conflicts, yet the evidentiary burden here is only moderate.

Board Quality

On paper, this is a good board. The roster spans finance, technology, health policy, provider delivery, and large-scale operations, and the governance framework is better than average: majority-vote elections, annual independence reviews, retirement at 72 unless waived, limits on outside board seats, no loans to directors, and direct access routes for shareholder complaints. The committee structure also looks serious, with dedicated Audit & Compliance, Corporate Governance, Finance & Technology, People Resources, and Executive committees.

The main weakness is structural, not personnel. Cigna has a lead independent director and 11 outside directors, but the chair role remains tied to management through the 2026 handoff because Cordani moves from CEO to Executive Chair rather than giving the board a truly independent chair. In a company carrying a Corporate Integrity Agreement through September 2028 and recurring PBM and AI-related scrutiny, that matters.

The Verdict

The upgrade path is straightforward: a genuinely independent chair after the July 1, 2026 CEO transition, plus another year or two of clean compliance execution, would make this look materially better. The downgrade path is just as clear: another significant enforcement action, or evidence that the board is rubber-stamping management while Cordani remains Executive Chair, would turn today’s manageable governance discount into a real trust problem.